FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced several promotions within the company's senior management team. Robin Washington, Chief Financial Officer (CFO), has been promoted to Executive Vice President; Paul Carter, formerly Senior Vice President, International Commercial Operations, has been promoted to Executive Vice President with responsibility for Gilead's worldwide commercial organization; and John McHutchison, MD, formerly Senior Vice President, Liver Disease Therapeutics, has been promoted to Executive Vice President and will assume additional responsibility for clinical development programs in the areas of oncology, respiratory diseases and inflammation.
"Robin, Paul and John have made significant contributions to Gilead, each demonstrating a commitment to improving systems and processes and advancing programs that will allow us to meet the needs of patients as quickly as possible," commented John C. Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences. "They have each built strong, capable teams and have helped Gilead navigate an increasingly complex environment as we expand geographically and into new therapeutic categories. Their leadership and vision will help ensure Gilead is able to achieve our goals and reach more patients in need around the world."
Ms. Washington joined Gilead in 2008 as Senior Vice President and CFO. She oversees the company's finance, information technology and investor relations functions, reporting to John Milligan, PhD, Gilead's President and Chief Operating Officer. Prior to joining Gilead, Ms. Washington was Chief Financial Officer of Hyperion Solutions, which was acquired by Oracle Corporation in March 2007. She previously served in a number of executive positions with PeopleSoft, most recently in the role of Senior Vice President and Corporate Controller. Ms. Washington is a member of the Board of Directors of Honeywell International, the Board of Directors of Salesforce.com and the Board of Visitors, Graziadio School of Business and Management, Pepperdine University. She is a certified public accountant and holds a bachelor's degree in business administration from the University of Michigan and an MBA from Pepperdine University.
Mr. Carter joined Gilead Sciences in April 2006 to head its European commercial organization. Later that year he assumed additional responsibility for Gilead's growing operations outside of Europe and North America. He has helped to establish the company's regional Asian headquarters in Hong Kong and numerous new affiliate offices, most recently including operations in the Czech Republic, Poland, Russia and South Korea. In his new role, Mr. Carter will oversee worldwide commercial operations, reporting to Dr. Milligan. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies. During his time with GSK, Mr. Carter gained increasing levels of senior experience as General Manager in Europe and later as a Regional Head of the International business in Asia. In this latter role he was also a member of GSK's International Management Committee. Mr. Carter's early experience includes several years with Arthur Andersen at its London office. He has a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the United Kingdom's Chartered Institute of Management Accountants.
Dr. McHutchison joined Gilead in 2010 as Senior Vice President, Liver Disease Therapeutics. In his newly expanded role, he will be responsible for Gilead's development programs in oncology, respiratory diseases and inflammation. Dr. McHutchison will continue to report to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke, Dr. McHutchison spent nearly 10 years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. Dr. McHutchison received bachelor of medicine and bachelor of surgery degrees from the University of Melbourne, Australia, and completed his residency in internal medicine and a fellowship in gastroenterology at the Royal Melbourne Hospital. He is also a member of the Royal Australasian College of Physicians.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)